 | • レポートコード：TPM-B04174 • 出版社/出版日：Transparency Market Research / 2017年10月 • レポート形態：英文、PDF、205ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、リウマチ治療薬の世界市場について調べ、リウマチ治療薬の世界規模、市場動向、市場環境、薬剤分類別分析、疾患別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・リウマチ治療薬の世界市場動向 ・リウマチ治療薬の世界市場環境 ・リウマチ治療薬の世界市場規模 ・リウマチ治療薬の世界市場規模：薬剤分類別 ・リウマチ治療薬の世界市場規模：疾患別 ・リウマチ治療薬の世界市場規模：流通経路別 ・リウマチ治療薬の世界市場：地域別市場規模・分析 ・リウマチ治療薬の北米市場規模・予測 ・リウマチ治療薬のアメリカ市場規模・予測 ・リウマチ治療薬の中南米市場規模・予測 ・リウマチ治療薬のヨーロッパ市場規模・予測 ・リウマチ治療薬のアジア市場規模・予測 ・リウマチ治療薬の日本市場規模・予測 ・リウマチ治療薬の中国市場規模・予測 ・リウマチ治療薬のインド市場規模・予測 ・リウマチ治療薬の中東市場規模・予測 ・リウマチ治療薬のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Rheumatology Therapeutics Market: Overview
Rheumatology is the discipline of internal medicine that involves the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are characterized by the inflammation that affects joints, tendons, ligaments, bones and sometimes organs. Rheumatic diseases are also called as musculoskeletal disease causes severe pain, deformity and morbidity and leads to heavy economic burden due to high cost of treatment. There are more than 100 different types of rheumatic diseases with different symptoms and the symptoms of these diseases to all age groups. The global prevalence of rheumatic diseases varies between 0.3-1% worldwide and is women are more likely to develop the symptoms of these diseases than men. the most common types of rheumatic disease includes the rheumatoid arthritis (RA), osteoarthritis (OA), gout , psoriatic arthritis, ankylosing spondylitis.
Out of the rheumatoid arthritis disease has high prevalence rates than other disease and accounts for the major share in global rheumatology therapeutics market. There are many different drugs and medications have been developed including biologics and biosimilars. Disease modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs are some of the most commonly used drugs for the treatment of different types of rheumatic diseases. The NSAIDs are widely and frequently used for the symptomatic treatment of rheumatoid arthritis and osteoarthritis. Most of the regulatory authorities recommends the use of DMARDs as the first line of treatment for rheumatoid arthritis after diagnosis of this disease.
Global Rheumatology Therapeutics Market: Drivers
The global rheumatology therapeutics market is projected to be driven by the increasing geriatric population in developed countries, increase in the number of new drugs approval and growing R&D investments. According to CDC, more than 54 million American are affected with arthritis in 2017 and it projected that by the end of 2025, this number would reach to 78 million. Also according to world arthritis day, more than 120 million people in European Union are affected by some of the forms of arthritis. The growing geriatric population in developed countries is likely to be key driving factor for global rheumatology therapeutics market.
The demand for the development of newer and technologically enhanced products such as biologics and biosimilars (generic of biologics) is growing globally. Hence, major players operating in the rheumatology therapeutics market are investing in research and development programs to develop new drugs. In 2015, Takeda Pharmaceuticals invested US$ 3.2 Bn in research and development activities. According to an annual report published by GlaxoSmithKline plc. In 2015, the company partnered with more than 1,500 companies and other academic organizations around the world for development of new drugs.
Global Rheumatology Therapeutics Market: Segmentation
Global rheumatology therapeutics market is broadly segmented into five segment based on drug class, disease indication, by route of administration, by distribution channel and by geography. By drug class, the market is segmented into disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs and others. DMARDs segment dominated the global rheumatology therapeutics market in 2016 owing to increase in usage of these drugs in early stage of disease and growing adoption of biologics drugs for treatment of moderate to severe rheumatoid arthritis and osteoarthritis.
The DMARDs are further sub-segmented into synthetic disease-modifying anti-rheumatic drugs and biologic disease-modifying anti-rheumatic drugs. Corticosteroids segment is projected to witness the highest growth rate during forecast period. By disease indication, market is segmented into rheumatoid arthritis (RA), osteoarthritis (OA), gout, ankylosing spondylitis, psoriatic arthritis and others. By route of administration market is segmented into oral route, parenteral route and topical. The distribution channel for rheumatology therapeutics market includes the hospital pharmacy, retail pharmacy and online pharmacy.
By Geography, the global rheumatology therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. These regions have been further segmented by countries, methods, applications and end-users. North America dominated the market and is anticipated to lose its market share to Asia Pacific region by the end of 2025.
Global Rheumatology Therapeutics Market: Competitive Analysis
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global rheumatology therapeutics market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in the rheumatology therapeutics market include Amgen, Inc., AbbVie, Inc., Pfizer, Inc. , Janssen Biotech, Inc. (Johnson & Johnson), Novartis AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.), Bristol-Myers Squibb Company, Merck & Co., Inc. , Sanofi, and Takeda Pharmaceutical, among others.
Global Rheumatology Therapeutics Market is segmented as given below:
Global Rheumatology Therapeutics Market, by Drug Class
Disease Modifying Anti-rheumatic Drugs (DMARD’s)
Synthetic Disease Modifying Anti-rheumatic Drugs
Biologic Disease Modifying Anti-rheumatic Drugs
Nonsteroidal Anti-inflammatory Drugs (NSAID’s)
Corticosteroids
Uric Acid Drugs
Others
Global Rheumatology Therapeutics Market, by Disease Indication
Rheumatoid Arthritis
Osteoarthritis
Gout
Psoriatic Arthritis
Ankylosing Spondylitis
Others
Global Rheumatology Therapeutics Market, by Route of Administration
Parenteral Route
Oral Route
Topical
Global Rheumatology Therapeutics Market, by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Rheumatology Therapeutics Market, by Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Rheumatology Therapeutics market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Key Industry Developments
4.1.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
4.1.3. Global Rheumatology Therapeutics Market Outlook
Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Porter’s five forces analysis
Chapter 6. Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.3. Corticosteroids
6.3.4. Uric Acid Drugs
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
6.5. Key Trends
Chapter 7. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
7.3.1. Rheumatoid Arthritis
7.3.2. Osteoarthritis
7.3.3. Gout
7.3.4. Psoriatic Arthritis
7.3.5. Ankylosing Spondylitis
7.3.6. Others
7.4. Market Attractiveness Analysis, by Disease Indication
7.5. Key Trends
Chapter 8. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Route of Administration
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
8.3.1. Parenteral
8.3.2. Oral
8.3.3. Topical
8.4. Market Attractiveness Analysis, by Route of Administration
8.5. Key Trends
Chapter 9. Global Rheumatology Therapeutics Market Analysis and Forecasts, by Distribution Channel
9.1. Key Findings
9.2. Introduction
9.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Attractiveness Analysis, by Distribution Channel
9.5. Key Trends
Chapter 10. Global Rheumatology Therapeutics market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Global Market Scenario
10.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
10.3.1. North America
10.3.2. Europe
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
10.4. Market Attractiveness Analysis, by Region
Chapter 11. North America Rheumatology Therapeutics market Analysis and Forecast
11.1. Key Findings
11.2. Market size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
11.2.1. U.S.
11.2.2. Canada
11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
11.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
11.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.3.3. Corticosteroids
11.3.4. Uric Acid Drugs
11.3.5. Others
11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
11.4.1. Rheumatoid Arthritis
11.4.2. Osteoarthritis
11.4.3. Gout
11.4.4. Psoriatic Arthritis
11.4.5. Ankylosing Spondylitis
11.4.6. Others
11.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
11.5.1. Parenteral
11.5.2. Oral
11.5.3. Topical
11.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
11.6.1. Hospital Pharmacy
11.6.2. Retail Pharmacy
11.6.3. Online Pharmacy
11.7. Market Attractiveness Analysis
11.7.1. By Country/Sub-region
11.7.2. By Drug Class
11.7.3. By Disease Indication
11.7.4. By Route of Administration
11.7.5. By Distribution Channel
11.8. Key Trends
Chapter 12. Europe Rheumatology Therapeutics market Analysis and Forecast
12.1. Key Findings
12.2. Market size (US$ Mn) Forecast By Country, 2017-2025
12.2.1. Germany
12.2.2. U.K.
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Russia
12.2.7. Rest of Europe
12.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
12.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
12.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.3.3. Corticosteroids
12.3.4. Uric Acid Drugs
12.3.5. Others
12.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
12.4.1. Rheumatoid Arthritis
12.4.2. Osteoarthritis
12.4.3. Gout
12.4.4. Psoriatic Arthritis
12.4.5. Ankylosing Spondylitis
12.4.6. Others
12.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
12.5.1. Parenteral
12.5.2. Oral
12.5.3. Topical
12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Route of Administration
12.7.5. By Distribution Channel
12.8. Key Trends
Chapter 13. Asia Pacific Rheumatology Therapeutics market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
13.3.1. China
13.3.2. India
13.3.3. Japan
13.3.4. Australia & New Zealand
13.3.5. Rest of Asia Pacific
13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
13.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
13.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.4.3. Corticosteroids
13.4.4. Uric Acid Drugs
13.4.5. Others
13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
13.5.1. Rheumatoid Arthritis
13.5.2. Osteoarthritis
13.5.3. Gout
13.5.4. Psoriatic Arthritis
13.5.5. Ankylosing Spondylitis
13.5.6. Others
13.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
13.6.1. Parenteral
13.6.2. Oral
13.6.3. Topical
13.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.7.1. Hospital Pharmacy
13.7.2. Retail Pharmacy
13.7.3. Online Pharmacy
13.8. Market Attractiveness Analysis
13.8.1. By Country/Sub-region
13.8.2. By Drug Class
13.8.3. By Disease Indication
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.9. Key Trends
Chapter 14. Latin America Rheumatology Therapeutics market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
14.3.1. Brazil
14.3.2. Mexico
14.3.3. Rest of Latin America
14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
14.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
14.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
14.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
14.4.3. Corticosteroids
14.4.4. Uric Acid Drugs
14.4.5. Others
14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
14.5.1. Rheumatoid Arthritis
14.5.2. Osteoarthritis
14.5.3. Gout
14.5.4. Psoriatic Arthritis
14.5.5. Ankylosing Spondylitis
14.5.6. Others
14.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
14.6.1. Parenteral
14.6.2. Oral
14.6.3. Topical
14.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
14.7.1. Hospital Pharmacy
14.7.2. Retail Pharmacy
14.7.3. Online Pharmacy
14.8. Market Attractiveness Analysis
14.8.1. By Country/Sub-region
14.8.2. By Drug Class
14.8.3. By Disease Indication
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.9. Key Trends
Chapter 15. Middle East and Africa Rheumatology Therapeutics market Analysis and Forecast
15.1. Key Findings / Developments
15.2. Market Overview
15.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
15.3.1. GCC Countries
15.3.2. South Africa
15.3.3. Israel
15.3.4. Rest of Middle East and Africa
15.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
15.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
15.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
15.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
15.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
15.4.3. Corticosteroids
15.4.4. Uric Acid Drugs
15.4.5. Others
15.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
15.5.1. Rheumatoid Arthritis
15.5.2. Osteoarthritis
15.5.3. Gout
15.5.4. Psoriatic Arthritis
15.5.5. Ankylosing Spondylitis
15.5.6. Others
15.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
15.6.1. Parenteral
15.6.2. Oral
15.6.3. Topical
15.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
15.7.1. Hospital Pharmacy
15.7.2. Retail Pharmacy
15.7.3. Online Pharmacy
15.8. Market Attractiveness Analysis
15.8.1. By Country/Sub-region
15.8.2. By Drug Class
15.8.3. By Disease Indication
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.9. Key Trends
Chapter 16. Competition Landscape
16.1. Global rheumatology therapeutics Market Share, by Company, 2016
16.2. Market Player – Competition Matrix (By Tier and Size of companies)
16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. AbbVie, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Pfizer, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Financial Overview
16.3.3.5. Strategic Overview
16.3.4. Janssen Biotech, Inc. (Johnson & Johnson)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Financial Overview
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Financial Overview
16.3.5.5. Strategic Overview
16.3.6. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Financial Overview
16.3.6.5. Strategic Overview
16.3.7. Bristol-Myers Squibb Company
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Financial Overview
16.3.7.5. Strategic Overview
16.3.8. Merck & Co., Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Financial Overview
16.3.8.5. Strategic Overview
16.3.9. Sanofi
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Financial Overview
16.3.9.5. Strategic Overview
16.3.10. Takeda Pharmaceutical
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Financial Overview
16.3.10.5. Strategic Overview
Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 06: Global rheumatology therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 11: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 16: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 17: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 18: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 22: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 23: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 28: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 29: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 30: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 31: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 32: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 33: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 34: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 35: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 36: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025